Pesquisar
Urogen Pharma Ltd
URGNAdicionar à lista de desejos
38.240USD
-2.850-6.94%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
1.86BValor de mercado
PerdaP/L TTM
Mais detalhes de Urogen Pharma Ltd Empresa
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Informações de Urogen Pharma Ltd
Código da empresaURGN
Nome da EmpresaUrogen Pharma Ltd
Data de listagemMay 04, 2017
CEOBarrett (Elizabeth A)
Número de funcionários235
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 04
Endereço9 Ha'ta'asiya St
CidadeRA'ANANA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal4365007
Telefone97297707601
Sitehttps://www.urogen.com/
Código da empresaURGN
Data de listagemMay 04, 2017
CEOBarrett (Elizabeth A)
Executivos da empresa Urogen Pharma Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
--
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
--
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Urogen Pharma Ltd?
Os cinco principais acionistas de Urogen Pharma Ltd são: Dr. Arie S. Belldegrun, M.D.
Quantas instituições possuem ações da Urogen Pharma Ltd (URGN)?
Em 2026Q1, 349 instituições possuíam ações da Urogen Pharma Ltd, com valor de mercado aproximado de 46.29M, representando 95.00% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -15691017.00.
Qual é a maior fonte de receita da Urogen Pharma Ltd?
Em 2026Q1, o segmento de negócios Jelmyto gerou a maior receita para Urogen Pharma Ltd, totalizando 93.99M e representando 85.61% da receita total.